Novartis AG
METHODS OF TREATMENT WITH ANTI-FACTOR XI/XIA ANTIBODIES

Abstract:

The present invention relates to methods of preventing, treating or managing, reducing the risk of stroke or thromboembolism in a subject afflicted with end stage renal disease comprising administering a pharmaceutical composition comprising a monoclonal antibody or an antigen binding fragment thereof that bind to human Factor XI and/or activated Factor XI ("Factor XIa").